Spearmint and caraway smell nothing alike. Both smells come from the same molecule, carvone. The atoms are identical, and only their arrangement in space differs, the way your left hand differs from your right. Chemists call the two versions mirror images.(1) (R)-carvone → spearmint / (S)-carvone → caraway In medicine, the two hands do not always behave the same way. In 1957, the German company Grünenthal began selling a drug called Contergan. Fotos: Jeanette Dietl - stock.adobe.com (Hintergrund); imago/JOKER Pregnant women took it against morning sickness. Each pill held thalidomide in both hands, half left and half right. Doctors linked the drug to serious birth defects, and it was pulled from sale in late 1961. More than 10,000 children worldwide are thought to have been affected (2). In 1979, researchers tested each hand on its own in animals. One hand had the calming effect. The other hand caused the birth defects (3). Birth defect due to thalidomide The obvious fix looks simple: sell the calming hand only. That fix fails inside the body. Within hours, each hand of thalidomide turns into the other (3, 4). A pill made only of the calming hand becomes a half-and-half mix again after the patient swallows it. Choosing the right hand at the factory would not have made the drug safe for pregnant women. Your body makes the same distinction between mirror images. It builds its proteins from one hand only. In a test tube, chemistry left to itself makes both hands in equal amounts. For more than a century, chemists had no explanation for how nature got from fifty-fifty to one hand only. On Wednesday 7 October 2026, the Royal Swedish Academy of Sciences gave the Nobel Prize in Chemistry to the two chemists who found the answer: Henri B. Kagan and Kenso Soai (5). Henri B. Kagan and Kenso Soai : Nobel Prize Chemistry 2026 Soai's experiment shows the idea in one number. In 1995, he put two teams of molecules in a flask, left hands and right hands. The teams were almost equal: 51 on one side, 49 on the other. Then the reaction started. Every new molecule came out the same hand as the molecule that helped make it, so the bigger team grew faster than the smaller one (6). Round after round, the gap got wider. In 2003, Soai ran a reaction that ended with one team only (5). Same atoms, opposite hands Your nose already knows Hold your two hands palm to palm. They match. Two hands palm to palm Now lay one on top of the other, both palms down, and the thumbs point in opposite directions. Two hands on top of each other Chemists call molecules with this property chiral, from the Greek word for hand (1). Back to the spearmint and the caraway seeds in your rye bread. Your nose tells the two carvones apart because the smell receptors inside it have a handedness of their own (1). A molecule of the wrong hand fits the receptor the way a left glove fits a right hand. Fifty-fifty in the flask, one hand in your cells Amino acids, the building blocks of proteins, also exist in two mirrored forms. The proteins in your cells use one of them. The other rarely appears in nature (2). Chemists call this homochirality, from the Greek for "same hand". Two enantiomers of a generic amino acid that are chiral When chemists ran reactions able to make both forms, the flask returned equal amounts of each. That result created two problems. The first was scientific: if chemistry left alone produces a fifty-fifty mix, something had to tip life toward one side. The second was commercial. In a medicine, only one mirror image produces the intended effect. The left-handed version of a drug may have one effect and the right-handed version another. Kagan, 1986: the output beat the input Chemists steer a reaction toward one hand with a catalyst, a helper molecule that takes part in the reaction and comes out unchanged. The working assumption was linear. A helper that is 50% pure in one hand gives a product about 50% pure in that hand. Double the purity of the helper and you double the purity of the result. In 1986, Henri Kagan and his team tested that assumption and broke it. In their reactions, the product came out purer in one hand than the helper they started with. Kagan named this deviation a non-linear effect (7). Your glove drawer shows the mechanism. Put 70 right gloves and 30 left gloves in a drawer. Pair every left glove with a right one and set the 30 pairs aside. Forty gloves stay loose, and every one of them is a right glove. Start: 70 right - 30 left = a 40-point lead for the right hand After pairing: 40 loose gloves, 40 right, 0 left = 100% right Catalyst molecules behave in a similar way. Partners of opposite hands lock together into pairs that do little or no work, and the majority hand stays free to run the reaction. In the systems chemists have studied in detail, the mixed pairs turn out to be the more stable ones (8). Soai, 1995 to 2003: a reaction that copies itself The sourdough principle A baker keeps a piece of yesterday's dough to start today's bread. The product of one batch seeds the next one. Chemists call a reaction whose product speeds up its own formation autocatalytic. Kenso Soai built a reaction in which the product molecule guides the formation of more of itself, with the same handedness. That is why the 51-to-49 mixture from the opening did not stay at 51 to 49. Each round of product served as the catalyst for the next round, and the majority hand made more of itself than the minority hand did (6). The 2003 result, one hand only, matters for a reason the Academy states plainly: Nobody other than life itself had achieved it before. Forty years from flask to Stockholm Count the years. Kagan's first decisive step dates from 1986, and the prize came in 2026. That makes 40 years. Soai's key paper is 31 years old. The committee also stayed honest about the limits. Somfai told the Associated Press that it is hard to point to one specific drug developed with these methods (7). The prize rewards an explanation of how one hand wins, and the Academy ties its pharmaceutical value to the chemists who design manufacturing reactions.. Run the same test on your CSR strategy Kagan and Soai answered one question: How a small imbalance at the start becomes total dominance at the end? A CSR plan built on proportional thinking assumes that inputs and outcomes move together, one euro of effort for one unit of impact. Chemistry showed in 1986 that this assumption fails. Here is the comparison, level by level. People Go back to thalidomide. A bottle of the harmless hand becomes a mixture once a patient swallows it. Purity at the point of production did not guarantee purity at the point of use. Your codes of conduct carry the same risk. A policy written cleanly at headquarters meets site managers, subcontractors and local incentives, and it changes form. The audit at headquarters checks the policy as written. Your workers experience the policy as applied. Kagan's result applies to boards as well. In October 2025, women held 38.2% of non-executive seats and 33.6% of all director seats in the EU's largest listed companies (9). Directive (EU) 2022/2381 set a target of 40% of non-executive seats, or 33% of all director seats, for listed companies by 30 June 2026 (10). Those figures measure the composition of the catalyst. Kagan proved that composition does not translate into the output in a straight line. No public dataset tracks how far each director shapes the final decision. Planet Agriculture shows the gain from picking the right hand. Metolachlor, a herbicide used on maize, contains mirror-image forms. Agronomists at Syngenta reported in 2002 that the S forms are about ten times more active than the R forms. The old mixed product required 2,000 to 3,000 grams per hectare. The S-enriched version, S-metolachlor, requires 1,200 to 1,900 grams for the same weed control (11). Low end: 1,200 / 2,000 = 0.60, so 40% less active ingredient High end: 1,900 / 3,000 = 0.63, so approximately 37% less. A farmer who switched puts approximately 37 to 40% less active ingredient on each hectare. Now the complication. Swiss researchers tracked metolachlor in Lake Baldegg from 1997 to 2001. The chemical fingerprint of the residues shifted to the new S product within a few years. Their data did not show lower total concentrations in the lake, because heavy rain during the spraying seasons made the year-to-year comparison unreliable (12). The dose reduction comes from the manufacturer's own agronomists. The independent lake data confirms the switch. It does not confirm the environmental benefit. Profit The classic industrial route to a single-hand molecule makes both hands and separates them afterwards. Run the arithmetic on that route. Reaction output: 50% right hand + 50% wrong hand Maximum usable yield: 50% Per 1 kg sold: at least 1 kg of the wrong hand, unless recycled You pay for the raw materials, solvents, energy and disposal of a molecule nobody buys. That waste sits on top of an already heavy load. Pharmaceutical manufacturing generates approximately 25 to 100 kilograms of waste for every kilogram of active ingredient, a range first set out through the E factor that the chemist Roger Sheldon introduced (13). Sheldon described one fine-chemical process in which the cost of disposing of its chromium waste approached the sales value of the product itself. CSR budgets carry the same blind spot. A sustainability line reported as spend counts the inputs. It says nothing about the share of that spend that produces the intended result, and nothing about the share that ends up as the corporate equivalent of the wrong hand. Why this chemistry earned the Nobel Prize For more than a century, chemists knew that life uses one hand and had no chemical mechanism that explained how one hand wins from an almost even start. Kagan showed that the purity of the output does not have to follow the purity of the input. Soai showed that a product able to copy itself turns a small lead into total dominance. The two results give origin-of-life research a working mechanism and give pharmaceutical chemists principles for designing reactions. Four chemistry prizes, one thread 2023, quantum dots (Bawendi, Brus and Ekimov): the size of a nanoparticle sets its colour. 2024, proteins (Baker, Hassabis and Jumper): computational design of new proteins and prediction of the shape of existing ones, the shape that sets each protein's job. 2025, metal-organic frameworks (Kitagawa, Robson and Yaghi): designed porous structures that trap large quantities of gas, with potential use in capturing greenhouse gases. 2026, mirror-image chemistry (Kagan and Soai): the handedness of a molecule decides what it does in your body and in a maize field. Look at what links the four. Each prize rewarded a discovery about the way matter is arranged. In a quantum dot, size sets the colour. A protein’s fold decides its job. The pattern of holes in a framework decides which gas it traps. With carvone, the hand decides between mint and caraway. Same atoms, different arrangement, different result. Now hold a CSRD report next to that list. The European Sustainability Reporting Standards ask mainly for totals, such as gross greenhouse gas emissions in tonnes of CO2 equivalent and the number of employees. A total works like a kitchen scale. Think back to the metolachlor case. A farm record shows how many grams of herbicide the farmer sprayed per hectare. It does not show whether the farmer used the old fifty-fifty mix or the product enriched in the active hand. A CSRD report works the same way. It counts how much a company emits, how many people it employs and how much it spends. It says far less about how those tonnes, people and euros are arranged inside the business. (1) Russell, G.F. and Hills, J.I., Odor differences between enantiomeric isomers, Science, 1971. https://pubmed.ncbi.nlm.nih.gov/5573954/ (2) CNN, German maker of thalidomide apologizes, 1 September 2012. https://edition.cnn.com/2012/09/01/health/germany-thalidomide-apology (3) Tokunaga, E., Yamamoto, T., Ito, E. and Shibata, N., Understanding the thalidomide chirality in biological processes, Scientific Reports, 20 November 2018. https://doi.org/10.1038/s41598-018-35457-6 (4) Proceedings of the National Academy of Sciences, Differentiation of antiinflammatory and antitumorigenic properties of stabilized enantiomers of thalidomide analogs, 2015. (5) Royal Swedish Academy of Sciences, Press release: The Nobel Prize in Chemistry 2026, 7 October 2026. https://www.nobelprize.org/prizes/chemistry/2026/press-release/ (6) Soai, K., Shibata, T., Morioka, H. and Choji, K., Asymmetric autocatalysis and amplification of enantiomeric excess of a chiral molecule, Nature 378, 767, 1995. https://www.doi.org/10.1038/378767A0 (7) Associated Press, via Anchorage Daily News, Nobel Prize in chemistry awarded to Kagan and Soai, 7 October 2026. https://www.adn.com/nation-world/2026/10/07/nobel-prize-in-chemistry-awarded-to-kagan-and-soai-for-untangling-mirror-images-in-molecules/ (8) In situ mass spectrometric and kinetic investigations of Soai's asymmetric autocatalysis, Chemistry: A European Journal, 2020. https://pmc.ncbi.nlm.nih.gov/articles/PMC7756584 (9) European Institute for Gender Equality, Gender balance in decision-making: largest listed companies, data for October 2025, published 2026. https://eige.europa.eu/sites/default/files/documents/202602335_pdf_mh0126044enn_002.pdf (10) European Parliament and Council, Directive (EU) 2022/2381 on improving the gender balance among directors of listed companies, 23 November 2022. https://eur-lex.europa.eu/eli/dir/2022/2381/oj (11) Roy, C., Guggiari, F. and Compagnon, J.M. (Syngenta Agro France), S-metolachlor, maize, sorghum and sunflower herbicide, 2002, record in FAO AGRIS. https://agris.fao.org/search/en/records/6472391b53aa8c896302c96f (12) Roy, C., Guggiari, F. and Compagnon, J.M. (Syngenta Agro France), S-metolachlor, maize, sorghum and sunflower herbicide, 2002, record in FAO AGRIS. https://agris.fao.org/search/en/records/6472391b53aa8c896302c96f (13) Sheldon, R.A., The E factor 25 years on: the rise of green chemistry and sustainability, Green Chemistry, 2017. https://pubs.rsc.org/en/content/articlehtml/2017/gc/c6gc02157c

Nobel season is our favourite week of the year. Six announcements, six chances to watch the world agree for a moment that evidence matters. On Monday 5 October 2026, Karl Deisseroth, Peter Hegemann, and Georg Nagel won the Nobel Prize in Medicine for their discoveries concerning light-gated ion channels and optogenetics (1). Karl Deisseroth, Peter Hegemann, Georg Nagel: Nobel Prize 2026 in Medecine To be simple, they gave science a light switch for individual brain cells. Shine blue light and a chosen type of neuron fires. Shine yellow light on a different protein and the neuron goes silent. The response comes within milliseconds, in a living, moving animal. Light switch for brain cells (created by AI) I trained as a physical and analytical chemist. The first lesson of my discipline is the distance between a signal and a cause. This prize rewards the people who closed that distance for the brain. Most sustainability reports I read have not started. Below, I explain the science in plain words. Then I hold it next to the way companies run CSR as a business model. Decades of watching Before explaining what this Nobel Prize is all about, let's agree on the definition of these two concepts: Correlation A correlation means two things change together. Causation Causation means changing one makes the other change. Ice cream sales and drownings rise together every summer. Nobody bans ice cream to save swimmers, because a third factor, hot weather, drives both. For most of modern neuroscience, researchers recorded the brain with four main tools: Electrodes that record electrical activity, Brain imaging, Lesions that destroy an area, and Drugs told them which areas lit up during fear, memory or movement. According to The Nobel Committee, these methods established correlations between brain activity and perception, movement, emotion and cognition (2). Each tool hits a limit before it reaches cause. Recording and imaging only watch. A scan shows the amygdala active while a person feels fear. That activity might produce the fear, follow from it, or run alongside it, driven by something else. Watching does not tell you which. Lesions and drugs intervene, but bluntly. Destroy an area and the behaviour disappears, yet that area holds many cell types mixed together, and the lesion removed all of them. A drug spreads to many cell types as well, and it acts far slower than neurons, which signal in thousandths of a second. Researchers learned that something in the region mattered. Which cells, and at which moment, stayed out of reach. Take your electricity bill. Your smart meter shows a spike every evening at seven. The meter will not tell you whether the oven, the heat pump or the gaming PC in your son’s bedroom caused it. You find out one way. You switch off one appliance at a time and watch the number. Neuroscientists had no such switch. Neurons of different types sit packed together, and neighbouring cells often drive opposite functions. Francis Crick wrote in 1999 that the ideal tool to control them would be light, and called his own idea "rather far-fetched" (3). Francis Crick The answer came from algae Chlamydomonas is a green alga made of a single cell, and it swims toward light. In 1991, Peter Hegemann and his colleague Harald Harz measured the tiny electric current (4) that starts that swim. It switched on within millionths of a second after a flash of light. Cells usually pass a signal along a chain of chemical steps, and chains take time. Hegemann concluded there was no chain. One single molecule had to catch the light and let the current through. Georg Nagel proved it. In 2002 and 2003, he took the algae gene for that molecule and placed it in frog eggs and in human kidney cells grown in the lab. When the team shone light on those cells, an electric current flowed. One molecule did both jobs: it sensed the light and opened a gate in the cell wall for electric charge. The team named it channelrhodopsin (5,6). Brain cells talk to each other with electric signals. In 2005, Karl Deisseroth’s team at Stanford put the algae gene into rat brain cells grown in a dish. Blue light made the cells fire on command, one signal per flash, as fast as the light blinked (7). Earlier teams tried lasers and dyes (2), which damaged the cells. Others built systems from several genes at once, and those reacted too slowly to keep up with a brain signal. The 2005 success then hung on a small detail. This algae molecule needs a helper, retinal, a form of vitamin A, to catch light. Nagel noticed that brain cells already carry enough of it, so nobody had to inject any (7). Count the years. The algae measurement came out in 1991. The Nobel call came in 2026. That is 35 years of research on pond algae with no product and no revenue line. How many projects in your R&D budget would survive 35 years of that? What the switch revealed Once researchers held a switch for specific cells, the brain stopped looking like a set of regions and started looking like a set of circuits. Three results matter for anyone who runs an organisation. In 2012, Stephan Lammel, Karl Deisseroth, Robert Malenka and colleagues showed that dopamine neurons in the same small brain region drive opposite states, reward in one case and aversion in the other, depending on which inputs reach them (8). In 2013, Steve Ramirez and colleagues in Susumu Tonegawa’s laboratory at MIT created a false memory. Mice froze in fear in a room where nothing bad had ever happened to them (9). In 2021, José-Alain Sahel, Botond Roska and colleagues reported that a blind patient with retinitis pigmentosa, treated with an optogenetic gene therapy and engineered goggles, regained enough vision to locate high-contrast objects on a table. The result covers one patient and partial vision, after decades of work. Several clinical trials are now under way (10, 2). Hold your CSR report up to the same light Companies have the brain’s old problem. Activity shows up everywhere, and causes show up nowhere on the dashboard. Here is the comparison, level by level. People An annual engagement survey records the whole organisation at once, the way an electrode on the scalp records the whole brain. Scores drop in one department. The cause sits somewhere among the manager, the shift pattern, the pay grid and the open-plan floor, and the survey will not say where. The Lammel result applies here. Two teams on the same floor respond in opposite directions to the same policy. A company-wide wellbeing programme averages them into a flat line. Which of your People initiatives have you ever switched off at one site and kept at another, to see what changed? Planet The environmental disclosure platform, found in 2021 that supply chain emissions average 11.4 times a company’s own operational emissions (11). In a 2023 report, approximately 41% of responding companies disclosed at least one category of those supply chain emissions (12). Run the arithmetic for an average company. Operational emissions equal 1 unit, supply chain emissions equal 11.4 units, total equals 12.4. A report that covers operations alone covers approximately 8% of the footprint. Pre-2005 neuroscience recorded the surface of the skull. The Planet equivalent is a carbon report that stops at the factory gate. Which supplier category would you target first if you had to prove a reduction, not estimate one? Profit Optogenetics answers two questions about any cell. Switch it on: is it sufficient to produce the behaviour? Switch it off: is it necessary? Apply the same two tests to each line of your CSR budget. Turn the programme off. Does revenue move, does risk move, does anyone outside the communications team notice? The Ramirez experiment has a commercial twin. Greenwashing plants a memory of virtue in customers who never saw anything green happen. The European Union has noticed. Directive (EU) 2024/825 on empowering consumers for the green transition bans generic environmental claims without recognised proof, and member states apply it from 27 September 2026. Ten days ago, the false memory became a legal liability. Why optogenetics earned a Nobel Prize The Nobel Prize in Physiology or Medicine rewards, in the Nobel Assembly’s words, the most important discoveries for the benefit of humankind. For more than a century, brain science watched the brain and guessed at causes. Optogenetics lets researchers test them. They switch a chosen group of cells on and see whether a behaviour appears, then switch it off and see whether it disappears. A guess becomes proof. The method also left the lab bench of its inventors. Laboratories around the world now use it, as the Nobel Assembly noted on announcement day. It has given one blind patient partial sight, and several clinical trials are now under way. Researchers also hope it will make cochlear implants more precise than today’s electrical devices. None of it began as a plan to cure anything. A few scientists wanted to know how a single-celled alga finds the light. Harz and Hegemann published their algae recording in Nature in 1991. Thirty-five years later, Stockholm called. Conclusion This prize completes a pattern. 2023, mRNA (Karikó and Weissman): messenger RNA delivers instructions to make a protein on demand. Their key finding was a small chemical change to the RNA that switches off the immune system's false alarm against it. Without that change, the vaccine triggers inflammation. With it, the instruction gets through. 2024, microRNA (Ambros and Ruvkun): tiny RNA molecules silence specific genes. Every cell carries the same DNA, and microRNAs decide which instructions a muscle cell ignores and which a brain cell ignores. 2025, regulatory T cells (Sakaguchi, Brunkow and Ramsdell): these cells and the Foxp3 gene act as brakes on the immune system. Remove the brake and the body attacks itself, causing autoimmune disease. 2026, optogenetics (Deisseroth, Hegemann and Nagel): a light-triggered switch that turns chosen neurons on or off within milliseconds. Companies invest heavily in growth engines and rarely in their own off switches. Few have a governance mechanism that stops a programme when evidence shows it fails, or a brake that catches a strategy before it damages the business. Four Nobel committees in a row rewarded control systems, while most boards still reward expansion. (1) https://www.nobelprize.org/prizes/medicine/2026/press-release/ (2) https://www.nobelprize.org/prizes/medicine/2026/advanced-information/ (3) https://royalsocietypublishing.org/rstb/article-abstract/354/1392/2021/19541/The-impact-of-molecular-biology-on-neuroscience?redirectedFrom=fulltext (4) https://www.nature.com/articles/351489a0 (5) https://www.science.org/doi/10.1126/science.1072068 (6) https://www.pnas.org/doi/full/10.1073/pnas.1936192100 (7) https://www.nature.com/articles/nn1525 (8) https://www.nature.com/articles/nature11527 (9) https://www.science.org/doi/10.1126/science.1239073 (10) https://www.nature.com/articles/s41591-021-01351-4 (11) https://www.cdp.net/es/press-releases/environmental-supply-chain-risks-to-cost-companies-120-billion-by-2026 (12) https://www.hlc.com/en/publications/cdp-reports-limited-progress-on-scope-3-nature-related-disclosure

Pink October campaign Every October, someone will ask you to buy something pink. A shampoo. A yogurt. A candle. A bucket of chicken. Part of the price goes to the fight against breast cancer, and the ribbon on the label tells you whose side the company is on. Nobody will ask what is inside the bottle. Last October I opened a talk with a photograph of a man in a suit. Under the photo I wrote his profile: male, white, 70 kilos, 25 to 40 years old, stable hormones, no chance of pregnancy. Medicine calls him the reference patient. Drugs, devices and safety limits were built around his body. The women in that room had spent their whole lives being measured against him. Reference patient Forty-one Octobers What Pink October is If you have never heard of Pink October, here is the short version. Every October, charities, hospitals, brands and governments turn things pink. The message to women is simple: get screened for breast cancer, and give money to fight it. The month started in the United States in October 1985. Its founders were the American Cancer Society and the pharmaceutical arm of Imperial Chemical Industries, at the time one of the largest chemical companies in the world. That arm later became part of AstraZeneca, a major seller of breast cancer drugs. From day one, the goal was to promote mammography. The ribbon came seven years later. In 1992, Evelyn Lauder of Estée Lauder and Alexandra Penney, editor of Self magazine, handed out 1.5 million pink ribbons in Estée Lauder stores across New York [1]. By the end of the decade, the movement was global. Brest cancer awareness month A chemical company helped start the month. A cosmetics company gave it its colour. Keep both facts in mind for the rest of this article. So what did 41 years of pink buy? Real progress on one number. In high-income countries, 83% of women diagnosed with breast cancer survive. In low-income countries, more than half of the women diagnosed die from it. [3] Belgium is one of seven countries meeting the WHO target of a 2.5% drop in breast cancer deaths every year. Screening saves lives. At the same time, globally, 2.3 million women were diagnosed in 2022 and 670,000 died. In half of the countries examined, the rate of new cases rose by 1 to 5% a year. By 2050, new cases are projected to climb by 38% and deaths by 68%. Screening finds the cancer. It does nothing to stop the cancer from starting. To prevent cancer from happening , you need to do prevention. Larousse defines prevention as the set of measures taken to prevent a danger, a risk or a harm, and the organisation in charge of putting those measures in place. That gives two halves: the measures, and someone answerable for them. Now the official kit. The European Code Against Cancer, 5th edition, published in October 2025 "14 ways you can help prevent cancer".[5] Every recommendation incriminates you. Do not smoke. Avoid alcohol. Breastfeed your baby. Take part in screening. At work, inform yourself about cancer-causing factors and ask your employer to protect you. Against air pollution, take public transport. The chemicals in your shampoo, your cosmetics and your food packaging appear in none of the fourteen. To be fair, this edition adds 14 recommendations for policy-makers, a first in the code's history. They cover tobacco taxes, alcohol prices, air quality limits and industrial emissions. Consumer product chemistry is missing there too. Industry appears once, as a risk to manage: governments are asked to protect the recommendations against undue industry interference. So the Larousse definition is half met. The measures exist. The organisation in charge of them turns out to be the woman herself, with fourteen tasks on her list, while the companies that formulate what she puts on her skin have none. In 2010, Barbara Brenner, then head of the watchdog group Breast Cancer Action [6], said in public that the world did not need any more awareness. Sixteen Octobers later, awareness is the one thing Pink October produces in surplus. Barbara Brenner Read the ribbon as a business model The parallel Let's forget that Pink October is about cancer awareness, and let's see it as a simple business model. A company sells more of its product in October. A slice of each sale goes to a charity. The more it sells, the more it gives, and the better it looks. Revenue, donation and reputation all grow with volume. In most European countries, the tax office then gives back part of the gift. The gesture is generous, deductible and photogenic. Now look at what stays the same: the product, the formula, the supplier and the volume. Philanthropy is kindness with a tax receipt. A CSR strategy works on the business model itself. It changes how the company earns its money and who pays when the product causes harm. A company that gives 50 cents per pink bucket has a charity budget. A company paid for the result instead of the volume has a strategy. Philantropy is not a CSR strategy Since 2004, the UN Industrial Development Organization has promoted a different model, called Chemical Leasing. The supplier stops selling tonnes. It sells the function the chemical performs: parts cleaned, surfaces coated, kilos of laundry washed. The customer pays for the result, and every extra litre of chemical becomes a cost for the supplier instead of revenue. The supplier now has a direct reason to use less, and to know exactly what it puts in. In our previous article [7], we showed how Signify, Michelin and Rolls-Royce sell light, kilometres and flying hours, so the seller pays for every unit that fails. Pink October works the other way round. The seller earns goodwill on every unit sold. If anything inside the product causes harm, the bill reaches the woman and her health system years later, long after the ribbon is in the bin. Hold those two models side by side. One rewards selling more. The other rewards needing less. Let see now what that means, pillar by pillar. The ribbon goes on the outside ENVIRONMENT Companies report carbon. Tonnes of CO2, scope 1, scope 2, a reduction target for 2030. The chemistry of what they sell gets a paragraph, if it gets one at all. Start with a word most consumers never learned: endocrine disruptor. Your body runs on hormones. A hormone is a chemical message that tells a cell what to do. An endocrine disruptor is a substance that interferes with that message. It copies the hormone, it blocks the hormone, or it scrambles the signal. Breast cancer is often hormone-driven. You see where this goes. The cost of these chemicals is no secret. In 2016, a team led by Leonardo Trasande [8] calculated that exposure to endocrine disrupting chemicals costs the European Union a median of €163 billion a year, 1.28% of EU GDP. Divide by 365 and you get approximately €447 million a day. The authors priced only the chemicals with the strongest evidence and said a wider analysis would push the bill higher. Read the list of diseases they put a price on. IQ loss, autism, ADHD, endometriosis, fibroids, obesity, diabetes, undescended testicles, male infertility, and deaths linked to low testosterone. Breast cancer is not on it. The most quoted euro figure on endocrine disruptors leaves out the disease Pink October was built for. So the real bill is higher than €163 billion. How much higher? We do not know. Let's talk about Phtalates. Phtalates Phthalates are chemicals that make plastic soft and help fragrances last. The link between phthalates and breast cancer is not settled. Studies disagree. Some find nothing. Hold that thought. A Danish study followed 1.12 million women over almost 10 million woman-years. Most phthalate exposures showed no link to breast cancer. Women with high cumulative exposure to one phthalate, dibutyl phthalate, through medicines formulated with it, had approximately double the rate of hormone-sensitive breast cancer. Lower doses showed no link.[9] One line in the funding section deserves a second look: part of the money for that study came from Susan G. Komen for the Cure. Remember the name. A narrow finding. Also the exact kind of finding a risk committee exists to price. A board that waits for certainty on a chemical in its product line is a board that has decided to let a regulator set the timing. Brussels already set it. On 31 March 2023, the European Commission published a regulation that created new hazard classes for endocrine disruptors under the EU rules on classification and labelling, known as CLP. [10] Substances already on the market must be classified under the new rules by 1 November 2026. Mixtures already on the market follow by 1 May 2028 (Dutch Board for the Authorisation of Plant Protection Products and Biocides). Count from April 2023 to October 2026 and industry had approximately 43 months of notice. Forty-three months. How many board meetings is that? How many of them had "endocrine disruptors" on the agenda? Go back to the two business models. A company that sells volume buys ingredients on price and asks the supplier for a safety data sheet. A supplier paid for the function carries the cost of every gram it adds, so it has every reason to know what each gram does. One model reads the hazard data at the deadline. The other reads it at the design stage. Take your best-selling product and print its list of ingredients. For each ingredient, write down two things: who checked whether it disrupts hormones under the new EU rules, and on what date. If you leave both blanks empty, your company has no idea whether that product will need a new formula after 1 November. A pink ribbon on a product you never checked costs you nothing in October, but it may cost you a reformulation, new labels and your reputation later. The threshold was built for someone else SOCIAL Go back to the man in the suit. In 1977, the US Food and Drug Administration issued a guideline that kept most women of childbearing age out of early clinical research. The FDA formally reversed it in 1993.[11] Sixteen years. Many drugs approved before the early 1990s, some still prescribed today, were tested in trials where women were missing or barely present.[12] The reference patient did not stay in the pharmacy. He moved into the medical devices too. During the pandemic, doctors relied on pulse oximeters, the small clip on your finger that reads the oxygen in your blood. In December 2020, researchers at the University of Michigan compared those readings with blood tests. When the clip showed a healthy 92 to 96%, the blood test showed dangerously low oxygen in 11.7% of readings from Black patients, against 3.6% from white patients.[13] The gap is approximately 3.2 times. The device worked. It worked for the body it was calibrated on. Oximeter Chemical safety follows the same logic. A safety limit tells you how much of a substance a body tolerates. Which body? The phthalate research hints at the answer. In a US study of five ethnic groups, the risk of breast cancer among Native Hawaiian women rose with exposure to eight of ten phthalates measured. The only earlier study of its kind had found nothing, in a group of mostly white women.[14] Missing data does not mean missing risk. It means nobody looked. Here the business model matters again. A model that sells volume needs one average customer, and the average customer looks a lot like the man in the suit. A model paid for results has to deliver for every customer it serves, including the ones furthest from the average. Those customers are where the failures show up first, and where the seller pays first. My position is simple. Set the threshold on the most exposed body, and every other body is protected by default. Set it on the reference patient, and the people least like him carry the risk without ever being told. Whose body set the safety limit for the product you sell? Do you know? Does your supplier know? The person who made the promise pays GOVERNANCE In April 2010, KFC turned its buckets pink. [15] For every pink bucket, restaurant operators donated 50 cents to Susan G. Komen for the Cure. The campaign raised $4.2 million. At 50 cents a bucket, that is approximately 8.4 million buckets of chicken (4,200,000 ÷ 0.50). KFC Pink Campaign Breast Cancer Action called it pink washing, a term the group coined for companies that wrap themselves in the ribbon while selling products linked to the disease.[16] KFC answered that its ads featured the grilled chicken. One part of the money paid for research on what women are exposed to. Another part came from a bucket nobody audited. That bucket is the volume model in its purest form. The donation grew with every bucket sold. Nothing in the contract asked what was in the bucket. CSRD now applies only to companies with more than 1,000 employees and more than €450 million in turnover. Approximately 90% of the companies previously covered are now out [17]. Most of the companies I work with earn between €50 million and €500 million a year. Under €450 million, the reporting duty is gone. Fewer reports. Fewer questions. Fewer pages where a phthalate would ever appear. Now the irony. The duty to report shrank in February. The duty to classify grows on 1 November. Two different teams own those two duties. The sustainability team writes the report. Regulatory affairs reads the supplier's safety data sheet. Which document does your board read? A product as a service-based contract answers that question without a committee. The party that chose the ingredient is the party that pays when the ingredient becomes a problem. No report cycle sits between the decision and the bill. Run the math. Profit equals revenue minus cost. A pink campaign books revenue in October. A forced reformulation books cost later, on a deadline written in Brussels in 2023. The marketing team takes credit for the first number. Who takes the second? Climate has its own version. A company publishes a carbon target, plants trees, and buys offsets, while its product line stays the same. Same logic, different colour. Governance exists to close that gap. In ESG language, governance means board committees, audits, disclosure rules, and sustainability reports. All of that machinery has one job: force someone to answer for a risk they created. So look at what happened to the machinery this year. In February 2026, the EU approved the Omnibus package. Mandatory sustainability reporting under The math of profits Two numbers belong on your next board agenda. The revenue from your pink campaign this month. The cost of replacing every ingredient in that pink product that meets the new endocrine disruptor criteria. If the second number does not exist yet, your C-suite/ board has approved a campaign without knowing what it is selling. Who on your C-suite/Board signed off on the pink packaging? Who signed off on the formula inside it? Is it the same person? Detection is a budget line. Prevention is a design choice. Pink October and recycling share a business model. Both clean up after the product. Neither touches the product. Recycling sorts the waste after the sale. Screening finds the tumour after the exposure. Both deserve funding. Neither one changes what goes into the bottle. Pink October asks women to check their bodies. Fair enough. Checking works. A campaign that only asks the patient to act leaves the product off the hook. The woman gets the mammogram. The bottle gets the ribbon. As a physical chemist, I read the label before I read the slogan. Earlier I asked you to keep the mixed evidence on phthalates in mind. Here is why. Mixed evidence is the normal state of chemical risk, and Brussels has stopped waiting for it to clear. The new CLP rules include a category called "suspected endocrine disruptors for human health," created for exactly this situation [18]. A board that hides behind "the science is not settled" will find that the regulation already has a box for unsettled science. The companies that get ahead of it will be the ones whose boards stopped asking "are we sure it causes harm?" and started asking "what will it cost us when the classification says it might?" Forty-one years of awareness taught women to check their bodies. A contract that makes the seller pay for what it puts in teaches the seller to check its formula. Pink October ends on 31 October. The EU Classification, Labelling and Packaging deadline for substances already on the market falls on 1 November 2026. [1] https://aparte.mu/en/article/pink-october-40-ans-de-lutte-contre-le-cancer-du-sein [2] Gayle A. Sulik, Pink Ribbon Blues : How Breast Cancer Culture Undermines Women's Health, 424 pages, published 28 October 2010. [3] https://news.un.org/en/story/2025/02/1160391 [4] https://ecommons.aku.edu/eastafrica_fhs_mc_gen_surg/142/ [5] https://cancer-code-europe.iarc.who.int/wp-content/uploads/2025/10/European-Code-Against-Cancer-5th-edition.pdf [6] https://en.wikipedia.org/wiki/Breast_Cancer_Action [7] https://www.science-by-trianon.com/post/the-companies-that-got-richer-by-never-selling-you-their-product [8] https://pmc.ncbi.nlm.nih.gov/articles/PMC5244983/ [9] https://ascopubs.org/doi/10.1200/JCO.18.02202 [10] https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32023R0707 [11] https://orwh.od.nih.gov/toolkit/recruitment/history [12] https://www.medidata.com/en/life-science-resources/medidata-blog/women-in-clinical-trials-history/ [13] https://pmc.ncbi.nlm.nih.gov/articles/PMC7808260/ [14] https://link.springer.com/article/10.1186/s13058-021-01419-6 [15] https://www.qsrweb.com/news/kfc-campaign-raises-more-than-4-million-for-breast-cancer-research/ [16] https://www.npr.org/sections/health-shots/2010/04/breast_cancer_awareness_in_a_b.html [17] https://bpma.co.uk/eu-gives-final-approval-for-csrd-and-csddd-simplification/ [18] https://dguv.de/ifa/fachinfos/endokrine-disruptoren/regulatorik/index-2.jsp

Your CSR sustainability strategy is destroying shareholder value. Find out exactly how much, and what it takes to reverse it. Trianon Scientific Communication identifies where ESG decisions erode profit across pharmaceutical, chemical, agro-food, textile and energy sectors, then rebuilds them around economic reality. 180+ documented transformations. Up to 80% profit increase. P³ methodology. Your Sustainability Strategy is Destroying Shareholder Value! What is Your Uncomfortable Question? We ask the uncomfortable question your homogeneous board can't see We spot the value destruction, then turn it into up to 60-80% profit. ex: Climate Change is making people sick. People sick drives your profits. Why should you care about global warming? 200+ Transformations - 6 industries SEE MORE UNCOMFORTABLE QUESTIONS What is Your Uncomfortable Question? About Trianon Scientific Communication Trianon Scientific Communication rebuilds sustainability strategies that actually work economically. While other consultancies validate your existing approach with inspirational messaging, we expose why it's failing, then fix it. Founded by Dr Audrey-Flore Ngomsik (PhD in physical & analytical chemistry, Vice President of Brussels Capital Region Climate Committee), and Dr Markus Fanselow (PhD in chemistry), our proprietary P³ pre audit financial liability assessment integrates People, Planet, and Profit simultaneously, quantifying exactly where strategies create value and where they destroy it. The result: 60-80% profit increases across 200+ implementations in pharmaceutical, textile, food, energy, materials, and chemicals. We answer provocative questions with data, not morals. We challenge assumptions with mathematics, not hope. And we deliver economic transformation. Brussels-based, serving internationally. MORE ABOUT US From Skepticism to Strategy How we work with clients. Three stages. One goal. Turn your sustainability challenges into competitive advantage. OUR PHILOSOPHY Our Services The Three-Stage Transformation Journey Your sustainability strategy could increase profit by 60-80%. Or cost you millions if you do nothing. Most companies can't tell the difference because they can't quantify what matters. Our transformation journey fixes that: Keynote speaking We challenge the assumptions your strategy depends on, we answer provocative questions with data, not moral arguments. STAGE 1: The Provocation Stage 2: The Transformation 6 Month Strategy Program We redesign your business model around economic reality. By building comprehensive diagnostic, then delivering implementation support that embeds change into procurement, operations, and capital allocation. Board advisory We provide ongoing board-level strategic support to sustain competitive advantage as markets shift and competitors catch up. Stage 3: The Partnership BOOK A DISCOVERY CONVERSATION Stage 1: The Provocation KEYNOTE SPEAKING We deliver keynote presentations that: Expose what's not working, the uncomfortable economic truths behind sustainability strategies, Show you the economic case for rebuilding it, Make your leadership team question everything they thought they knew about sustainability. Pharmaceutical executives. Textile manufacturers. Food companies. Cosmetics brands. Energy providers. Materials producers. MORE ABOUT STAGE 1 Example Of Uncomfortable Questions To Start The Conversation Pink in October, Exposed all year: Endocrine disruptors and hormone-dependent cancers Why should pharma care about sustainability when sick people means more profit? For Pharmaceuticals Your problem might not be sustainability per se, but the solution always is. All industries Climate change innovation: Do board inherent & acquired diversity matter? For all industries Bio-Based Doesn't Always Means Sustainable. For Product Companies Farming for the future: Reality or Utopia? For Food Industry AI: Sustainability Savior or Silent Threat? For all Industries Waste: A Side Story. For all Industries TELL US YOUR UNCOMFORTABLE QUESTION What happens next? Organizations that can handle uncomfortable truths backed by data book a discovery conversation. BOOK A DISCOVERY CONVERSATION MORE STRATEGIC KEYNOTE TOPICS Stage 2: The Transformation 6 to 24 MONTH STRATEGY PROGRAM We redesign your business model around economic reality. Not compliance checklists. Not sustainability theater. Not incremental improvements. Economic recalibration that turns your biggest sustainability challenge into measurable competitive advantage. Food. Pharma & Healthcare. Cosmetics. Energy. Materials. Textile. Artificial Intelligence. MORE ABOUT STAGE 2 Our Approach P³ exposure diagnostic (4 weeks) A comprehensive pre audit financial liability assessment & roadmap delivery. We quantify the gap between your sustainability strategy and economic reality. Then we ask the question that exposes why the gap exists. And We make the economic business case to drive environmental & social (DEI) sustainability in your company. Framework design (3- 6 Months) We rebuild your approach around what actually works economically. Implementation support (6-24 Months) We don't just tell you what to do, we help you build the systems to do it MORE ABOUT OUR P³ DIAGNOSTIC BOOK A DISCOVERY CONVERSATION What happens next? Successful transformations often convert to ongoing advisory relationships (Stage 3 ). INDUSTRIES WE SERVE Recent Case Study Pharmaceutucal company CASE STUDY 1 Organic snack company CASE STUDY 2 Public Affairs & Policy CASE STUDY 3 Stage 3: The Partnership BOARD ADVISORY For organizations that recognize they need us in the room when critical decisions get made. All Industries. Policy & Public Affair Organisations. MORE ABOUT STAGE 3 This is Board-level advisory Strategic council on major business decisions Sparring partner for CEO a trusted, impartial advisor who provides a safe, confidential space for leaders to challenge assumptions, explore strategic options, and refine decisions. Crisis advisory When your sustainability strategy meets unexpected reality Strategy refinement that spots risks comfortable insiders never see Continuous improvement Direct access to our science, policy and entrepreneurship insights. Outcome: Sustained competitive advantage Primarily available to organizations we've already transformed through Stage 2. ADVISORY ENQUIRY We're Selective About Who We Work With Not every organization is ready for uncomfortable truths. What's the Uncomfortable Question Your Organization Is Avoiding? The pattern is consistent : Scepticism at the beginning, Strategy at the end. TELL US YOUR UNCOMFORTABLE QUESTION Frequently asked questions General Our Methodology Events What is Trianon Scientific Communication? Trianon Scientific Communication is a sustainability strategy consultancy that helps companies figure out why their sustainability strategies cost money instead of making it. We work with companies brave enough to question their assumptions. Our clients don't need convincing that sustainability matters, they need frameworks that work economically. We solve complex problems with science, systems thinking, and uncomfortable honesty. What makes Trianon different from other sustainability consultancies? Trianon was founded when Dr. Audrey-Flore Ngomsik and Dr Markus Fanselow, 2 pioneers in sustainability. They realized the sustainability consulting industry had a fundamental problem: everyone was selling the same solutions without questioning whether the underlying business models could support them. Recycled plastic costs 73% more than virgin alternatives. Pharmaceutical companies profit from disease. Carbon offset programs create markets for greenwashing. These aren't secrets. They're just uncomfortable truths most consultants politely ignore. We built a firm on a different premise: Real sustainability requires real economic logic. And real economic logic requires asking questions that make boardrooms uncomfortable. Today, Trianon delivers its methodology across Europe, Africa, and Asia. Our team has helped 200+ companies turn sustainability from compliance burden into competitive advantage, not through hope, but through economic recalibration that works. What is the P³ methodology? P³ stands for People, Planet, Profit, integrated simultaneously, not siloed. Most companies optimize one dimension (usually Planet) and destabilize the others. Our methodology integrates all three, which is why we achieve 60-80% profit increases while meeting sustainability requirements. This has been proven across 180+ implementations in pharmaceutical, textile, food, manufacturing, energy, and chemical industries. Who is Dr. Audrey-Flore Ngomsik? Dr. Audrey-Flore Ngomsik is CEO and Co-Founder of Trianon Scientific Communication, holding a PhD in Physical and Analytical Chemistry from Sorbonne University. She serves as Vice President of the Brussels Capital Region Climate Committee and is a board member of the European Policy Centre. Known for her UNAPOLOGETIC approach, she asks provocative questions backed by data, such as challenging pharmaceutical executives on why they should care about climate when illness drives profits. She is the author, currently writing the "Statistical Anomaly" (September 2026). What results has Trianon achieved? Trianon's P³ methodology has delivered 60-80% profit increases across 180+ implementations. Specific examples include: a €50M pharmaceutical company achieving 80% profit increase over 3 years; a €200M textile manufacturer saving €35M through avoided regulatory fines and new revenue streams; and a €100M food company reducing costs by 57% while meeting CSRD compliance requirements. Has your methodology been peer-reviewed? Yes, you can find the article is called: Beyond the financial balance sheet: Embracing the Triple Bottom Line for Sustainable Business Success and can be downloaded for free here How is Trianon's approach different from traditional sustainability consulting? Traditional sustainability consulting delivers reports and compliance frameworks. Trianon delivers profit increases. The key differences: (1) We start with Provocation, not "best practices", challenging the assumptions your strategy depends on; (2) We quantify everything in financial metrics, not just ESG scores; (3) We implement strategic programs, not just recommendations, embedding change into procurement, operations, and capital allocation; (4) We measure success in quarterly earnings impact, not only sustainability ratings. Data over moral arguments, economics over inspiration, results over platitudes.

Executive training for sustainable business leaders outperforming competitors. Strategic development programs providing the specialized expertise that transforms environmental challenges into revenue growth and market leadership. CORPORATE SOCIAL RESPONSIBILITY EXECUTIVE TRAINING Accelerate your business sustainable transformation Make your business sustainable and profitable! Your fast track to sustainable corporate leadership RESERVE YOUR SEATS What Our Clients Say "The insights I gained are already making a positive impact on my business" Hector R, Entrepreneur "An eye opening experience! The training gave me the confidence to champion sustainability initiatives at the board level." Daniel N., Executive consultant The transformation program transformed how I approach sustainability in my executive role. Highly recommended for any leader looking to drive meaningful change" Sarah C., Chief Operation Officer Why CSR is essential. 51 - 81% More profitable in 3 to 5 years for companies applying sustainable practices 89% of entrepreneurs and SMEs need to accelerate their transition to sustainable practices 36 - 56% Lower profits for companies that fail to improve their environmental and social impact Are you facing these challenges? In today's business landscape, sustainable practices aren't just an option—they're a catalyst for growth. Organizations with strong CSR practices show up to 80% higher profitability over 3 year. Building a sustainable business model Entrepreneurs often find it challenging to develop a business model that balances profitability with social responsibility. The CSR training equips participants with the tools to create sustainable strategies that not only enhance their brand image but also contribute positively to society, helping them stand out in a competitive market. Engaging stakeholders effectively Many professionals grapple with the challenge of engaging stakeholders (employees, customers, and investors) in their sustainability initiatives. This training offers practical techniques for fostering collaboration and buy-in from all parties, which is crucial for the success of any CSR strategy. Measuring impact & ROI Determining the effectiveness of CSR initiatives can be daunting, especially for those without a background in sustainability metrics. The training addresses this challenge by teaching participants how to measure the impact of their efforts accurately and demonstrate the return on investment (ROI) of their CSR activities, making it easier to justify continued investment in sustainability initiatives. By addressing these challenges through your training program, you can effectively appeal to professionals and entrepreneurs who are eager to enhance their skills and drive meaningful change within their organizations. Driving innovation & growth through CSR Professionals and entrepreneurs often struggle to integrate Corporate Social Responsibility (CSR) into their innovation strategies. Many organizations view CSR as a separate initiative rather than a core component of their business model. This disconnect can stifle creativity and limit growth opportunities. The training program will equip participants with the knowledge to leverage CSR as a catalyst for innovation, enabling them to develop sustainable products and services that meet evolving market demands while enhancing their competitive edge. Avoiding greenwashing & social washing As consumers become more discerning about corporate claims regarding sustainability and social responsibility, the risk of greenwashing and social washing has increased. Professionals face the challenge of ensuring their organizations communicate authentically about their CSR efforts without misleading stakeholders. This training will provide essential strategies for developing transparent, measurable, and genuine CSR initiatives, helping participants build trust with their audience and avoid the reputational damage associated with deceptive practices. By addressing these challenges in your marketing materials, you can effectively appeal to professionals and entrepreneurs who are eager to enhance their skills in navigating the complexities of CSR while fostering innovation and maintaining credibility in their sustainability efforts. Strategic integration While 76% of executives consider sustainability strategic, only 22% have clear implementation roadmaps. Bridge this gap by learning to: → Align sustainability with core business objectives → Develop actionable implementation strategies → Create measurable impact frameworks Take your next step towards sustainable success! INVEST IN YOU & YOUR STAFF Six modules What do you really know about climate change? This interactive session aims to evaluate comprehension levels of the IPCC reportand identify areas for further education and action. Understanding CSR and its importance You will review key concepts, diving into the intricate dynamics of understanding CSR and its pivotal role in driving business success. Foundations of Diversity, Equity and Inclusion in business. This module is designed to equip participants with the fundamental principles and strategies for integrating DEI practices into organizational frameworks. Navigating social and green washing You'll gain invaluable knowledge for recognizing deceptive practices and distinguishing genuine sustainability efforts. How to measure your impact Participants will acquire the skills needed to align business strategies with stakeholder expectations and prioritize sustainability initiatives. Drafting your CSR strategy Participants will explore strategies for integrating these two aspects (environmental & social sustainability) seamlessly into organizational frameworks, thereby promoting holistic sustainability practices. Three modules (to go deeper) Linking environmental and social sustainability to build sustainable business models. Participants will explore strategies to integrate both aspects seamlessly into organizational frameworks, fostering holistic sustainability practices that benefit society, the business and the environment. Sustainable supply chains This module explores strategies for creating and managing supply chains that prioritize environmental sustainability, ethical sourcing, and social responsibility, ensuring alignment with global standards. CSR innovation and emerging trends Participants will explore cutting-edge trends in CSR, such as the integration of AI in sustainability reporting, circular economy models, and innovative approaches to address climate change and social equity challenges. The benefices of our training course Results obtained 12 months after the end of the training Increased revenues Up to 39% increase in revenues through effective sustainable practices. Reduced energy consumption Up to 75% reduction in energy consumption thanks to sustainable practices. Waste reduction Up to 20% waste reduction with effective CSR strategies. Reduced staff turnover Up to 25% reduction in turnover thanks to responsible social practices. Optimized risk management Reducing risks by 16% to 36% with a solid CSR strategy. Pragmatic teaching approach Interactive, fun and directly applicable to your business. Your fast-track to sustainable leadership INVEST IN YOURSELF & YOUR STAFF The journey to becoming a visionary leader starts here. INVEST IN YOU & YOUR STAFF 6 Modules for professionals 3 Modules for experts 3 hours per module delivered in 6 weeks 500€ per person per module. Ask for a quote if you want to train more than 10 people from the same organisation What if your next step as a leader could transform not just your business, but the future of our planet? DISCOVER OUR TRANSFORMATION PROGRAM Our team of professionals Dr Audrey-Flore Ngomsik PhD in physical & analytical chemistry CSR strategist Dr Markus Fanselow PhD in chemistry Sustainability architect Affiliated consultants Experts from Trianon Sci Comm network CSR training in numbers 190+ Leaders trained 95% Success rate 22 Countries represented 4.8/5 Clients'satisfaction Quote First name* Last name* Email* Company name* Where are you located?* City, Country VAT ID Position* Address* What is the website of your company?* Who will follow the training?* Yourself Several people in your organisation How many people will follow the training (If you don't know yet write an estimation)* What is your preferred language for the training?* French English What is your preferred format for the training?* Online face to face Mixed format Which modules are you interested in?* Module 1: What do you really know about climate change? Module 2: Understanding CSR and its importance Module 3: Foundations of Diversity, Equity and Inclusion in business. Module 4: Navigating social and green washing Module 5: How to measure your impact Module 6: Drafting your CSR strategy Module 7: Linking environmental and social sustainability to build sustainable business models. Module 8: Sustainable supply chains Module 9: CSR innovation and emerging trends What will be the location of the training?* Yes, subscribe me to your newsletter. * When would you like the training to happen? Submit Need more information? Contact Us Frequently asked questions How flexible is the program format? Choose between online or face to face sessions with the ability to mix formats based on your preference and availability. Do the pricing include VAT? For Belgium residents (B2B & B2C) : PRICE + VAT For other EU residents with a VAT number (B2B) : PRICE (VAT reverse charge applies) For other EU residents with no valid VAT number (B2C): PRICE + VAT What if I can't attend all sessions? To support continued learning, the participant will receive the highlights of the missed session. Where will be held the face to face sessions? Individuals registering for the cohort have the flexibility to participate in the course either online or face-to-face in Brussels, ensuring accessibility for all professionals eager to enhance their CSR knowledge and skills. For organizations with 10 or more participants, our training can be conducted onsite, providing a tailored experience that fits your team’s specific needs. This training can be scheduled over three consecutive days or spread out, depending on your preference. Please note that travel costs will apply for onsite training.

Dr. Audrey-Flore Ngomsik: Sustainability expert speaker & board advisor. From business strategy to technical systems, from sustainability economics to AI ethics. She answers uncomfortable questions with data. What is Your Uncomfortable Question? STRATEGIC EXECUTIVE KEYNOTES CHECK AVAILABILITY Dr Audrey-Flore Ngomsik Makes C-Suite uncomfortable and Scientists think differently She will ask the questions your leadership team has been avoiding. Then show them what avoiding them has already cost. What is Your Uncomfortable Question? We Believe in The Power of Communication About Us This is the space to introduce visitors to the business or brand. Briefly explain who's behind it, what it does and what makes it unique. Share its core values and what this site has to offer. Learn More ABOUT Dr Audrey-Flore Ngomsik She will ask your leadership team the question their five-year plan is built on. 80% of organisations that book this keynote engage for follow-on transformation work within six months. ASK YOUR UNCOMFORTABLE QUESTION 80% Corporate keynotes are followed-up with an engagement within 6 months 330+ Keynotes across 4 continents TEDx International speaker in French & English 3 domains. Env & social sustainability. Science. Entrepreneurship Dr Audrey-Flore Ngomsik in numbers LEARN MORE ABOUT DR NGOMSIK 20+ years in sustainability 15+ years board experience up to 80% profit increased achieved in 5 years 3 pillars People, Planet, Profit 3 domains science, entrepreneurship, policy ASK FOR PRICING What happens after the keynote THE SETTING €50M pharmaceutical company · Annual executive retreat. THE QUESTION ASKED "Climate change makes people sick. You're a pharma company. people getting sick is good for your business. Why should you care? THE RESULT Initial resistance. Then uncomfortable silence as executives realized their growth strategy had a fatal flaw they'd been politely ignoring. THE FOLLOW-UP CEO commissioned immediate strategy review. Three months after the keynote, the same company engaged for a full P³ transformation programme. What Happens After the Keynote The Setting: €50M pharmaceutical company, annual executive retreat The Question: "Climate change is making people sick. We're a pharmaceutical company. People getting sick is good for business. Why should we even care about sustainability?" The Reaction: Initial resistance. Then uncomfortable silence as executives realized their growth strategy had a fatal flaw they'd been politely ignoring. The Follow-Up: CEO commissioned immediate strategy review. Three months later, they engaged Trianon for a 6-month transformation program. Result: 80% profit increase over 3 years by redesigning their sustainability strategy around economic reality, not moral rhetoric. That's €40M additional profit, from a single keynote that made them uncomfortable. 80% of organizations that book my keynotes engage for follow-up transformation work within 6 months. "Dr. Ngomsik’s knowledge, expertise, and ability to communicate complex ideas through clear, relatable anecdotes are always on full display. An obviously talented speaker." Chief sustainability officer · Annual leadership conference Pharmaceutical sector · Belgium · 200-person C-suite audience "Audrey-Flore is an outstanding speaker: intelligent, captivating, funny, and committed! How can you not be hooked to her lips when Audrey-Flore speaks?" CEO - Textile company Company leadership meeting Provocative business strategy keynotes I customize every keynote around the uncomfortable question YOUR organization is avoiding, then show you what the data actually says and why ignoring it costs millions. Most speakers are either provocative business strategists OR technical experts. I'm both. That means I can challenge your C-suite in the morning and discuss energy storage chemistry with your engineers in the afternoon. The keynotes I deliver fall into two tracks: I Don't Deliver Pre-Packaged Talks Designed to captivate and inspire, these talks focus on strategic insights and transformative ideas. Ideal for C-suite executives, leadership forums, and large conferences. Recent Examples: AI: Sustainability savior or Silent threat? Is AI truly the answer to our sustainability challenges, or are we overlooking its hidden costs? This talk moves beyond the hype to address critical environmental, social, and business considerations. I'll provoke thought, inspire action, and encourage a more holistic understanding of AI's role in creating a sustainable future. When CSR becomes strategy Is your CSR program actually driving change, or is it just expensive window dressing for investors? This talk cuts through the corporate sustainability theater to expose what actually moves the needle. We fixed the Ozone Layer. So why can't we fix climate change? Innovate to last Companies ignoring climate and social urgency aren't just bad corporate citizens, it is business malpractice. Regulators are circling, investors are pulling out, customers are switching brands, and your best talent is already updating their LinkedIn profiles. Yet most boardrooms still treat sustainability like expensive charity work instead of what it actually is: survival strategy with a profit margin. This talk challenges the myth that environmental action is a trade-off against performance. I'll show you why that's not just wrong, it's financially reckless. We'll explore how visionary companies don't just "adapt" to climate reality, they rewrite the playbook entirely. Hidden innovators: Untold stories that shape the world Behind nearly every "breakthrough" we celebrate, there are women whose contributions were erased, minimized, or outright stolen. From space exploration to HIV research, drug safety to climate science, the real architects of progress were systematically written out of the story. This isn't a feel-good diversity lecture. It's an interactive investigation into why our mythologized version of "genius" is costing us solutions to today's biggest challenges. You'll uncover the hidden figures whose insights transformed medicine, computing, and physics, then ask the question no one wants to answer: if we erased this much talent from history, how much are we still ignoring today? These keynotes combine storytelling, humour, and data to deliver a message your audience will remember, and act on. ASK FOR PRICING Keynotes about technical innovation and systems For organizations seeking in-depth, scientific & actionable knowledge tailored to their industry on systems and scalability (food, pharma, cosmetics, textiles, materials, energy). For engineers, R&D teams, and technical conferences. Recent Examples: C.S.R is here to stay Is circular economy THE answer for more sustainability ? Sustainable innovations How to enhance a more sustainable cosmetics industry? Regenerative sustainability Sustainable food & farming Decolonising sustainability Become an authentic and useful ally for DEI A disability inclusive transition to a low carbon economy The link between CSR, ESG and SDG The return on investment on social sustainability Rethinking leadership for a sustainable future Ideal for internal teams, strategy sessions, and executive training, these sessions transform complex scientific concepts into practical tools for decision-making. ASK FOR PRICING Why this speaker, not another one. Translate environmental & social sustainability into practical business decisions, connecting science, strategy, sector realities, leadership priorities, and measurable P&L impact. PhD in physical and analytical chemistry Most consultants tell you what's wrong. Most scientists tell you what's possible. Most policy experts tell you what's coming. Dr Ngomsik is the rare professional who tells you what transforms industries with the data to back it up. VP Brussels Climate Committee Her international experience, from Europe to Asia and Africa, gives her unmatched insight into multicultural and sectoral sustainability challenges. Her clients see results: up to 80% profit increases and better decision-making from diverse leadership teams. Multi awarded international experience MORE ABOUT DR NGOMSIK PhD in physical and analytical chemistry Show why sustainability matters today, with science-backed insights your audience can relate to. Translate sustainability into practical business decisions, connecting strategy, sector realities, leadership priorities, and measurable P&L impact. VP Brussels Climat Committee She identifies opportunities invisible to traditional approaches. Most consultants tell you what's wrong. Most scientists tell you what's possible. Most policy experts tell you what's coming. Dr Ngomsik is the rare professional who tells you what transforms industries with the data to back it up. International experience Her international experience, from Europe to Asia and Africa, gives her unmatched insight into multicultural and sectoral sustainability challenges. Her clients see results: up to 80% profit increases and better decision-making from diverse leadership teams. Multiple awards and recognition Al Gore Climate Reality Leadership Corp (2025) Best CSR Consulting firm in Europe by Acquisition International (2025-2026) Finalist Western European Green Tech Startup Awards by Global Startup Awards (2025) Most inspiring women in Sustainability (2024) by American Association of Women in Sustainability Finalist Veuve Clicquot Bold Woman Award (2024) #22 - LinkedIn Top 50 EU Sustainability Influencer (2024) Finalist Woman Award in STEM and Technology (2024) by Innoviris Why chose Dr Ngomsik for your event? As a conference organizer, you need a speaker who can: Show why sustainability matters today, with science-backed insights your audience can relate to. Translate sustainability into practical business decisions, connecting strategy, sector realities, leadership priorities, and measurable P&L impact. Inspire immediate action, giving delegates tools and ideas they can apply right away, whatever their level of experience. Every keynote is tailored to your company and audience, ensuring relevance, engagement, and impact. Sustainability is not a "nice to have" Done strategically, it unlocks growth, protects margins, and strengthens your market position. Whether your organization is just starting its sustainability journey or looking to deepen an advanced strategy, Dr. Audrey-Flore Ngomsik makes sustainability understandable, actionable, and inspiring. Most consultants tell you what's wrong. Most scientists tell you what's possible. Most policy experts tell you what's coming. Dr Ngomsik is the rare professional who tells you what transforms industries with the data to back it up . She started working on environmental & social challenges when people were still scared of the word "SUSTAINABILITY" HER VALUE PROPOSITION She identifies opportunities invisible to traditional approaches. Her international experience, from Europe to Asia and Africa, gives her unmatched insight into multicultural and sectoral sustainability challenges. Her clients see results: up to 80% profit increases and better decision-making from diverse leadership teams. A TEDx speaker and climate advisor to governments, she translates scientific complexity into actionable, engaging narratives, using humor to break resistance and provoke fresh thinking. “Your problem may not be sustainability. But the solution? It is.” Awards & Recognitions Al Gore Climate Reality Leadership Corp (2025) Best CSR Consulting firm in Europe by Acquisition International (2025) Finalist Western European Green Tech Startup Awards by Global Startup Awards (2025) Most inspiring women in Sustainability (2024) by American Association of Women in Sustainability Finalist Veuve Clicquot Bold Woman Award (2024) #22 - LinkedIn Top 50 EU Sustainability Influencer (2024) Finalist Woman Award in STEM and Technology (2024) by Innoviris Think of me as your sustainability translator: I speak fluent Science, Business, and Policy, and I can teach your organization to speak all three Why Choose Me Why I'm not your typical sustainability speaker 01 I was doing sustainability before it had a name PhD Physical & Analytical Chemistry, Sorbonne University. I started solving sustainability problems in 2004, back when "green" was just a color and most boardrooms thought carbon footprint was something hippies worried about. Here's what two decades in the lab taught me that MBA programs won't: real sustainability breakthroughs don't happen in strategy decks. They happen when you understand why one polymer bonds differently than another, how molecular structure determines whether a material can actually be recycled (or just gets greenwashed), and which chemical processes are burning money while claiming to save the planet. I've watched entire industries bet billions on "sustainable" solutions that violate basic chemistry. I've seen C-suites reject profitable innovations because they couldn't distinguish science from science fiction. And I proved, in peer-reviewed research published in the International Journal of Business Administration, what I've known since my first article: sustainability ROI isn't soft metrics and stakeholder feelings. It's quantifiable, it's molecular, and it's sitting in your operational inefficiencies right now. Most sustainability experts translate business problems into environmental language. I translate molecular realities into profit margins. 02 I prove profit, not preach Most sustainability conversations force you to pick a side: financial performance or environmental responsibility. Quarterly results or long-term impact. But what if that's the wrong question entirely? Here's what I've learned managing €25M P&L and advising companies across industries: your problem might not be sustainability per se, but the solution always is. The companies that will lead aren't choosing between false binaries. They're embracing a different reality: Profit and purpose. Efficiency and empathy. Innovation and impact. Not as trade-offs, but as multipliers. I've watched organizations transform sustainability from cost center to competitive advantage, not through sacrifice, but through smarter strategy. The insight that changes everything? Sustainability isn't about doing less harm. It's about unlocking value that was always there, hidden in inefficiencies we've normalized. The question isn't whether you can afford to prioritize sustainability. It's whether you can afford not to. 03 I shape policy, not just opinions Most sustainability consultants read policy briefs and make predictions. I sit on the Experts Climate Committee of the Brussels Capital Region and the Governing Board of the European Policy Centre. When regulations shift, I'm often in the room where it happens. But here's why that matters to you: I don't operate in just one domain. I move between lab benches and boardrooms, between molecular innovation and policy corridors, between startup execution and institutional influence. That's rare, because most experts are either technical scientists who've never managed P&L, or business strategists who couldn't explain a carbon bond if their quarterly results depended on it, or policy advisors who've never actually implemented what they recommend. I've delivered profitable sustainability transformation at scale because I understand what works in all three worlds: the chemistry that makes solutions viable, the business model that makes them scalable, and the regulatory landscape that makes them inevitable. Global recognition and board appointments followed, not because I chased awards, but because cross-cultural fluency and policy influence open doors that credentials alone never will. The advantage? When I explain where sustainability is headed, it's not speculation. It's pattern recognition from inside the system that's reshaping your industry, whether you're ready or not. don't treat environmental, social, and economic sustainability as separate initiatives. They understand these are interconnected systems that, when aligned properly, create unprecedented competitive advantages. The organisations that truly succeed when companies were still afraid of environmental regulations and social responsibility was considered charity. I was in Sorbonne laboratories developing solutions for industrial pollution while business schools were teaching that profit and purpose were incompatible. My journey began before "sustainability" was trendy I've seen the evolution from compliance-driven approaches to strategic integration. Today, I help mid-market companies ($50M-$500M) avoid the mistakes larger corporations made and build sustainability into their competitive DNA from the start. That early start gave me a unique perspective: Here's what I've discovered after two decades of holistic sustainability work: Sustainable strategy that fits your reality Beyond the buzz words BOOK YOUR GAME-CHANGING KEYNOTE HERE IS WHAT I WILL NOT DO Show up with a generic sustainability deck and pretend the chemical industry faces the same challenges as fashion, or that cosmetics can solve problems the same way food systems do. I won't recycle the same TED talk across every conference room, drop buzzwords like "circular economy" without addressing your sector's specific barriers, or ignore the hard trade-offs your industry actually faces. BECAUSE SUSTAINABILITY IS NOT ONE SIZE FITS ALL The path to decarbonization in chemicals looks nothing like it does in tech. Textile circularity hits fundamentally different barriers than food waste. And anyone selling you a universal playbook is either naive or doesn't care if it actually works for you. I WORK ACCROSS INDUSTRIES AND THEIR MESSY REALITIES From the staggering environmental cost of colour in textiles to building disability-inclusive pathways in the low-carbon transition. From sustainable food systems and green materials innovation to waste transformation that closes loops instead of creating expensive PR. From untangling the CSR-ESG-SDG alphabet soup to asking what a genuinely sustainable cosmetics industry would require beyond "clean beauty" Instagram posts. Each talk is adapted to your industry's specific constraints, opportunities, and the uncomfortable questions no one's asking in your boardroom yet. WHAT STAYS CONSTANT The challenge to move past performative sustainability toward strategies that are measurable, profitable, and actually transformative. Someone needs to tell your industry's specific truth, not just the sanitized version that fits nicely in your annual report. ASK FOR AVAILABILITY What's YOUR Uncomfortable Question? These examples show the range, from business strategy to technical systems, from sustainability economics to AI ethics. But I don't show up with pre-packaged slides. I show up having interviewed your stakeholders, studied your industry's specific contradictions, and identified the question you're avoiding. Then I ask it, backed by data you can't dismiss. ASK US YOUR UNCOMFORTABLE QUESTION We needed a speaker who could talk to both our C-suite and our R&D team at our annual conference. Dr. Ngomsik did the opening keynote on business strategy, then a technical deep-dive on the sustainability of our food system, for our technical people. Both sessions had the highest engagement scores we've ever recorded. Not because people agreed with everything, because she made them think differently about problems they thought they understood. Daniel B. Chief Sustainability Officer Ask for pricing First name Last name Job Tittle* Website of your organisation Email* Event Date Audience (size, background, industry) * For which format would you like to book? Submit